10x Genomics Overview
Latest ROE for 10x Genomics: -9.1% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-9.10%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for TXG is -9.1%. That is below the Healthcare sector average of 22.76%. Investors often review this figure alongside 10x Genomics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, TXG currently prints -9.1% for ROE, while the sector average sits near 22.76%. That is roughly 140.0% below the sector mean. Large gaps often invite a closer look at 10x Genomics's growth, margins, and balance sheet.
Return on Equity shows how effectively 10x Genomics converts resources into returns. At -9.1%, TXG may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting TXG's ROE (-9.1%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack 10x Genomics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
